Farampator

Farampator

Clinical data
Other names	CX-691; ORG-24448
Legal status
Legal status	US: Investigational New Drug
Identifiers
IUPAC name 2,1,3-benzoxadiazol-6-yl-piperidin-1-ylmethanone
CAS Number	211735-76-1 Y
PubChem CID	4118151
ChemSpider	3331565 N
UNII	7X6P5N8K2L
KEGG	D04131 Y
CompTox Dashboard (EPA)	DTXSID90175413
Chemical and physical data
Formula	C12H13N3O2
Molar mass	231.255 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CCN(CC1)C(=O)C2=CC3=NON=C3C=C2
InChI InChI=1S/C12H13N3O2/c16-12(15-6-2-1-3-7-15)9-4-5-10-11(8-9)14-17-13-10/h4-5,8H,1-3,6-7H2 N Key:XFVRBYKKGGDPAJ-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Farampator (developmental code names CX-691, ORG-24448, SCH-900460) is an ampakine drug. It was developed by Cortex Pharmaceuticals, and licensed to Organon BioSciences for commercial development. Following the purchase of Organon by Schering-Plough in 2007, the development license to farampator was transferred. The development of farampator was eventually terminated, reportedly due to concerns about cardiac toxicity.

Farampator has been investigated for its effect on AMPA receptors and researched for potential use in the treatment of schizophrenia and Alzheimer's disease. It was found to improve short-term memory, but impaired episodic memory. It produced side effects such as headache, somnolence and nausea. Subjects reporting side effects had significantly higher plasma levels of farampator than subjects without. Additional analyses revealed that in the farampator condition the group without side effects showed a significantly superior memory performance relative to the group with side effects.

See also

• AMPA receptor positive allosteric modulator